Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Where is the outrage?

Maybe this from the 10-Q is why there's no MMP activity....

"PDS, our joint venture with TPL, has experienced significant declines in revenues while at the same time incurring significant legal costs associated with pending litigation with companies which we allege have infringed on our patent portfolio. Currently, there are no commitments by us or TPL to provide additional working capital to PDS and we do not intend to fund any cash requirements for PDS. We expect PDS will fund its operations through licensing revenue."

So PDS has burned through most of PTSC's investment (and loans?) as noted elsewhere in the 10-Q. Leckrone is sucking money in through his other patents, so why waste TPL time/money on MMP?

Isn't an action needed by PTSC as equal (if not majority - can someone add up the cash put in by PTSC v TPL?) partner in PDS (the joint venture) to hold TPL to "specific performance" under the various agreements and/or to have a court order TPL income held in escrow pending PTSC/TPL resolution? Or did the PTSC BOD really leave it as 'business as usual' for MMP and TPL.

OUTRAGED



Share
New Message
Please login to post a reply